Tell us what you think about Healio
Sign in for a personal experience.
Customized content served to meet your interests.
The novel anti–PD-1 antibody lambrolizumab was associated with response rates of more than 35% in a cohort of patients with advanced melanoma, according to study results.
The analysis included 135 patients. Researchers assigned patients to lambrolizumab (Merck) — previously known as MK-3475 — in one of three doses: 10 mg/kg IV every 2 weeks, 10 mg/kg every 3 weeks, or 2 mg/kg every 3 weeks.
Register for Healio to get content tailored to your specialty and areas of interest.
It’s FREE and only takes one minute.
View past polls »
©2013 All Rights Reserved.